Remember Me
Or use your Academic/Social account:


Or use your Academic/Social account:


You have just completed your registration at OpenAire.

Before you can login to the site, you will need to activate your account. An e-mail will be sent to you with the proper instructions.


Please note that this site is currently undergoing Beta testing.
Any new content you create is not guaranteed to be present to the final version of the site upon release.

Thank you for your patience,
OpenAire Dev Team.

Close This Message


Verify Password:
Verify E-mail:
*All Fields Are Required.
Please Verify You Are Human:
fbtwitterlinkedinvimeoflicker grey 14rssslideshare1
Publisher: BioMed Central
Languages: English
Types: Article
BACKGROUND: Worldwide, millions of people are treated each year for significant head injury. A substantial proportion die, and many more are disabled. If short term corticosteroid infusion could be reliably shown to reduce these risks by just a few percent then this might affect the treatment of a few hundred thousand patients a year, protecting thousands from death or long term disability. STUDY DESIGN: CRASH is a large simple, placebo-controlled trial of the effects of a 48-hour infusion of corticosteroids on death and on neurological disability, among adults with head injury and some impairment of consciousness. Head injured patients with impaired consciousness who are judged to be 16 years or older are eligible if the responsible doctor is, for any reason, substantially uncertain whether or not to use corticosteroids. ORGANISATION: The CRASH trial will determine reliably the effects on death and disability of a short corticosteroid infusion following significant head injury. To detect or refute improvements of only a few percent in outcome, many thousands of acute head injury patients must be randomised between control and steroid infusions. Such large numbers will be possible only if hundreds of doctors and nurses can collaborate in the participating emergency departments. Since they are busy, and working in emergency situations, the trial involves them in almost no extra work: no special investigations or changes to usual management are required, and data collection is absolutely minimal. The trial is on-going and new collaborators are welcome. Further information about the trial is available at www.crash.lshtm.ac.uk
  • The results below are discovered through our pilot algorithms. Let us know how we are doing!

    • 1. Jennett B, Teasdale G: Management of head injuries. Philadelphia. FA Davies, 1981
    • 2. Jennett B, Bond M: Assessment of outcome after severe brain damage. Lancet 1975, 1:480-484
    • 3. Alderson P, Roberts I: Corticosteroids in acute traumatic brain injury: systematic review of randomised controlled trials. BMJ 1997, 314:1855-1859
    • 4. Bracken MB, Shepard MJ, Collins WF, et al: A randomised controlled trial of methylprednisolone or naloxone in the treatment of acute spinal cord injury. N Eng J Med 1990, 322:1405-1411
    • 5. Otani K, Abe H, Kadoya S, et al: Beneficial effect of methylprednisolone sodium succinate in the treatment of acute spinal cord injury (translation of Japanese). Sekitsui Sekizui J 1994, 7:633-647
    • 6. Bracken MB, Shepard MJ, Holford TR, et al: Administration of methylprednisolone for 24 or 48 hours or tirilazad mesylate for 48 hours in the treatment of acute spinal cord injury. Results of the Third National Acute Spinal Cord Injury Randomized Controlled Trial. National Acute Spinal Cord Injury Study. JAMA 1997, 277:1597-1604
    • 7. Demopoulos HB, Flamm ES, Seligman ML: Further studies on free radical pathology in the major central nervous system disorders: effects of very high doses of methylprednisolone on the functional outcome, morphology, and chemistry of experimental spinal cord impact injury. Can J Physiol Pharmacol 1982, 60:1415-1424
    • 8. Anderson DK, Saunders RD, Demediuk P: Lipid hydrolysis and peroxidation in injured spinal cord: partial protection with methylprednisolone or vitamin E and selenium. Central Nervous System Trauma 1985, 2:257-267
    • 9. Braughler JM, Hall ED, Means ED, et al: Evaluation of an intensive methylprednisolone sodium succinate dosing regimen in experimental spinal cord injury. J Neurosurg 1987, 67:102-105
    • 10. Hall ED: High dose glucocorticoid treatment improves neurological recovery in head-injured mice. J Neurosurg 1985, 62:882- 887
    • 11. Hall ED: The neuroprotective pharmacology of methylprednisolone. J. Neurosurg 1992, 76:13-22
    • 12. Gaab MR, Trost HA, Alcantara A, et al: Ultrahigh dexamethasone in acute brain injury. Results from a prospective randomised double-blind multi-centre trial. Zentralblatt für Neurochirurgie 1994, 55:135-143
    • 13. Collins R, Doll R, Peto R: Ethics of clinical trials. In: Williams C, ed. Introducing New Treatments for Cancer. Chichester: John Wiley and Sons Ltd, 1991
    • 14. Ewan PW: Treatment of anaphylactic reactions. Prescribers' Journal 1997, 37:125-132
    • 15. Peto R, Pike MC, Armitage P, et al: Design and analysis of randomised clinical trials requiring prolonged observation of each patient. 1. Introduction and design. Br J Cancer 1976, 34:585-612
  • No related research data.
  • No similar publications.

Share - Bookmark

Download from

Cite this article